Novel antiplatelet agents and anticoagulants, along with fibrinolytic drugs and mechanical interventions, are revolutionizing the management of acute coronary syndromes.
Answers are grounded in this paper and cite their sources.
Requires prospective RCTs before changing ACS practice; leaves open optimal integration of these agents.
Therapies with novel antiplatelet agents and anticoagulants are the focus of current research. When used separately or in combination, these agents prevent generation of thrombin by activated platelets. The new therapies, in conjunction with judicious use of fibrinolytic drugs and mechanical interventions, are revolutionizing the management of patients with acute coronary syndromes.
No takes yet. Share an insight, caveat, or question.
Schneider et al. (1998) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: